Grifols SA
Grifols SA (GIKLY): 4 pipeline candidates. Updated within the last hour.
BioSniper Score
2-factor signal · derived from public data
N/A
N/A
Lead: Phase 3
4 candidates
N/A
N/A
A transparent, data-derived signal for Grifols SAacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.7B
Cash
—
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| albutein 20% | Phase 3 |
| flebogamma 5% dif | Phase 2/Phase 3 |
| grf312 5% | Phase 2 |
| smt + pe-a 5% | Phase 3 |
Frequently asked questions
How many drug candidates are in Grifols SA's pipeline?
Grifols SA (GIKLY) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Grifols SA's lead drug candidate?
Grifols SA's most advanced tracked candidate is albutein 20% (Phase 3) for Decompensated Cirrhosis and Ascites.
What is Grifols SA's market capitalization?
Grifols SA's market capitalization is approximately $7.7B.
Who is the CEO of Grifols SA?
Mr. Jose Ignacio Abia Buenache is the chief executive officer of Grifols SA (GIKLY).
Get the full picture on Grifols SA
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.